Pharmacogenetic profiling of gastric cancer patients treated with combination chemotherapy (fluoropyrimidines, platinum, taxanes) within clinical Phase II and Phase III studies.

(Cooperation with Prof. Jaeger/Dr. Al-batran, Krankenhaus Nordwest, Frankfurt)

Functional genetic polymorphisms of growth factors – impact on carcinogenesis of colorectal cancer and hepatocellular carcinoma

(Funded by grant of Deutsche Krebshilfe e.V., Cooperation with Prof. P. Schirmacher, Institute of Pathology Heidelberg, and Prof. Baretton, Institute of Pathology Dresden)

 

Analyses of Epidermal Growth Factor Receptor (EGFR) in cholangio-cellular carcinoma

(Funded by MeDDrive program University Dresden)

 

Analyses of response prediction in patients with colorectal cancer treated with 5-FU based chemotherapy – impact of allelic loss of the TS gene (LOH)

(Funded by grant of Erich und Gertrud Roggenbuck Stiftung, Cooperation with Prof. K. Pantel, Tumor Biology, University of Hamburg)

 

Impact of genetic modifications within the TS gene for efficacy of pemetrexed in patients with Non-Small-Cell-Lung-Cancer (NSCLC)

(Cooperation with Prof. A. Fissler-Eckhoff, HSK Klinikum Wiesbaden)

Pharmacogenetic profiling in colorectal cancer within several internal Phase III studies (e.g. PETACC-2, PETACC-8, EORTC 40015 etc.)

(Funded in part by grants of the EORTC-GI group, Cooperation with Prof. H.-J Lenz and Prof. R. Ladner, University of Southern California, Los Angeles)

 

Epidemiological analyses of newly identified genetic polymorphisms in different populations (Caucasians, Asians, Afro-Americans)

(Cooperation with Prof. M. Yu, University Minnesota)

Seitenanfang